European Commission Approves First Tocilizumab Biosimilar European Commission Approves First Tocilizumab Biosimilar

The biosimilar, commercially called Tyenne, is indicated to treat several autoimmune diseases as well as cytokine release syndrome and COVID-19.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Source Type: news